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Abstract
Background: Gastric cancer is the fourth most common cancer in the world and the second most prevalent cause
of cancer related death. The development of gastric cancer is mainly associated with H. Pylori infection leading to a
focus in pathology studies on bacterial and environmental factors, and to a lesser extent on the mechanistic
development of the tumour. MicroRNAs are small non-coding RNA molecules involved in post-transcriptional gene
regulation. They are found to regulate genes involved in diverse biological functions and alterations in microRNA
expression have been linked to the pathogenesis of many malignancies. The current study is focused on
identifying microRNAs involved in gastric carcinogenesis and to explore their mechanistic relevance by
characterizing their targets.
Results: Invitrogen NCode miRNA microarrays identified miR-449 to be decreased in 1-year-old Gastrin KO mice
and in H. Pylori infected gastric tissues compared to tissues from wild type animals. Growth rate of gastric cell lines
over-expressing miR-449 was inhibited by 60% compared to controls. FACS cell cycle analysis of miR-449 over-
expressing cells showed a significant increase in the sub-G1 fraction indicative of apoptosis. ß-Gal assays indicated
a senescent phenotype of gastric cell lines over-expressing miR-449. Affymetrix 133v2 arrays identified GMNN, MET,
CCNE2, SIRT1 and CDK6 as miR-449 targets. Luciferase assays were used to confirm GMNN, MET, CCNE2 and SIRT1 as
direct targets. We also show that miR-449 over-expression activated p53 and its downstream target p21 as well as
the apoptosis markers cleaved CASP3 and PARP. Importantly, qPCR analyses showed a loss of miR-449 expression
in human clinical gastric tumours compared to normal tissues.
Conclusions: In this study, we document a diminished expression of miR-449 in Gastrin KO mice and further
confirmed its loss in human gastric tumours. We investigated the function of miR-449 by identifying its direct
targets. Furthermore we show that miR-449 induces senescence and apoptosis by activating the p53 pathway.
Background
Gastric cancer is among the five most common cancers
in the world and the second most prevalent cause of
cancer-related deaths [1]. It is mainly, but not exclu-
sively, caused by H. Pylori infection [2] as not all of H.
Pylori infected persons develop tumours [3]. Other fac-
tors involved in the development of gastric cancer
include the degree and type of the inflammatory
response [2] as well as the levels of the Gastrin
hormone [4,5]. Several studies have shown that both
hypergastrinemia [6,7] and the lack of Gastrin [5] con-
tribute to the pathogenesis of gastric cancer. Achlorhy-
dria is a common feature of mouse models prone to
developing metaplasia and cancer [6,8,9]. Gastrin knock-
out mice are achlorhydric [10], favouring a bacterial gas-
tric overgrowth [11,12], and chronic bacterial gastric
infections lead to gastric metaplasia which may progress
into gastric cancer [6,12].
Since their discovery microRNAs, have been found
implicated in a very wide range of normal and pathologi-
cal processes [13]. MicroRNAs exert their regulatory
functions posttranscriptionally by binding to partly com-
plementary sequence motifs predominantly in the 3’
UTR of target mRNAs resulting in mRNA destabilization
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any medium, provided the original work is properly cited.and translational repression [14]. From a biological point
of view, microRNAs are challenging objects to study as
they regulate cohorts of target genes, which are not read-
ily identified. From a therapeutical point of view, micro-
RNAs are highly interesting as several studies have
demonstrated the power of microRNAs as biomarkers
and initial preclinical studies have established that micro-
RNAs may be therapeutically targeted in vivo [15].
Profiling studies have evidenced microRNA deregula-
tion in a broad spectrum of diseases including all major
cancers [16]. MicroRNAs likely affect tumourigenic pro-
cesses at two levels. Firstly, several studies have estab-
lished pro-oncogenic or tumour-suppressive roles of
individual microRNAs firmly linking these to cancer
etiology as exemplified by miR-155, miR-10b and miR-
21 [17-19]. Secondly, the microRNA regulatory system
per se appears to have tumour suppressive functions as
genetic ablation of key microRNA biogenesis factors,
such as Dicer, strongly increase cancer susceptibility
[20] and loss of function mutations have been identified
in important microRNAs processing factors in human
tumours [21-23].
In this study, we address the importance of micro-
RNAs in gastric cancer taking advantage of the Gastrin
knockout mouse model and H. pylori infection of wild
type mice. We identify miR-449 as significantly down-
regulated or lost in mouse models of gastric cancer as
well as in primary human gastric tumours. Identification
of mRNA targets reveals that this microRNA likely
exerts tumour suppressive functions through the con-
certed regulation of a cohort of cancer-associated cell-
cycle regulators including MET, GMNN, CCNE2,
SIRT1, and HDAC1.
Methods
Mice
Three different age groups (12-16 weeks, 1 year or 1½
years) of wild type (wt) or Gastrin knockout (KO) mice
were used. All mice were on a mixed 129/SvJ, C57BL/6J
background, backcrossed at least four times to C57BL/6J
[12]. The mice were kept under specific pathogen-free
conditions and monitored according to the Federation
of European Laboratory Animal Science Associations
recommendation [24] with 12 h light, 12 h dark cycles.
H. pylori infection
C57BL6/J mice (n = 10) were inoculated with a non-
mouse-adapted clone of H. Pylori strain 67:21, originally
isolated from an antral biopsy obtained from a Swedish
female with gastric ulcer. The strain is VacA
+ and con-
tains the entire Cag pathogenicity island (PAI) with
genetic stability in the Cag PAI [25]. The mice were
inoculated every second day (three times) during a 5-
day period. DNA was extracted and analyzed for the
presence of helicobacter species using a semi-nested
polymerase chain reaction-denaturing gradient gel elec-
trophoresis assay, specific for the genus helicobacter, as
described previously [26]. A matched group of unin-
fected C57BL6/J mice were used as controls.
The stomachs of all mice were dissected into fundus
and antrum prior to RNA extraction. All animal experi-
ments were approved by the Danish Animal Welfare
Committee (2005/562-40) and the Danish Forest and
Nature Agency (20010077355/6).
Mice antrum sections
Mice were sacrificed by cervical dislocation. The antrum
was removed, washed gently in ice-cold PBS, frozen
in liquid nitrogen and stored at -80°C until RNA
extraction.
Clinical samples analyses
Biopsies from gastric cancer and the adjacent normal
tissues were obtained from patients undergoing surgery
for gastric cancer at the Department of Gastrointestinal
Surgery, Rigshospitalet. The inclusion took place in July
to December 2008 and all patients provided signed,
informed consent (Ethical committee approval H-B-
2008-049) and Danish Data Protection Agency (2008-
41-2138). The biopsies were placed in RNAlater
(Ambion) in the operating room and subsequently fro-
zen at -80°C until RNA extraction.
RNA extraction and qPCR analyses
RNA was extracted using TRIzol (Invitrogen) according to
manufacturer. miRNA expression profile was assessed using
Taqman miRNA assays (Applied biosystems) for hsa/mmu-
miR-449a and b, hsa/mmu-miR-34a, b and c and rnu44 or
hsa/mmu-miR-191. Primer sequences for Affymetrix targets
validation are listed in additional file 1, table S1.
Cell culture
SNU638 and MKN74 were grown in RPMI-1640
(Gibco) with 10% FBS (Hyclone), 100U/ml penicillin
and 100 μg/ml streptomycin (Invitrogen) and incubated
at 37°C in 5% CO2. HCT116 cells (wt and p53-/- were
g r o w ni nM c C o y ’s 5A (Gibco) with 10% FBS (Hyclone),
and 100U/ml penicillin and 100 μg/ml streptomycin
(Invitrogen) and incubated at 37°C in 5% CO2. HEK293
a n dM E Fc e l l s( w ta n dp 5 3 - / - )w e r eg r o w ni nD M E M
(Gibco) with 10%FBS (Hyclone), 100U/ml penicillin and
100 μg/ml streptomycin (Invitrogen) and incubated at
37°C with 5% CO2.
miRNA precursors and siRNA
miRNA precursors were purchased from Ambion, hsa-
miR-449a (PM11521), hsa-miR-449b (PM11127) and
hsa-miR-34a (PM11030).
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SNU638 cells were seeded in 24-well plates and trans-
fected the following day with 50nM miRNA duplex or
siRNA using Lipofectamine 2000 (Invitrogen). Cells
were fixed at indicated time points in 4% paraformalde-
hyde, stained in a 0.1% crystal violet solution, and resus-
pended in 10% acetic acid. Sample absorbance was
measured at 620 nm.
Cell cycle FACS analyses
SNU638 and MKN74 cells were seeded at 2 × 10
6 cells
per 10cm plate and transfected with 50nM miRNA
duplex (Ambion) using Lipofectamine 2000 (Invitrogen).
Cells were harvested 48 and 72 hours post-transfection,
stained for DNA content using propidium iodide (PI)
a n da n a l y z e do naF A C SC a l i b u rf l o wc y t o m e t e r
(Becton-Dickinson). Briefly, cells were harvested by tryp-
sinization and washed once with PBS before fixing over
night in 70% EtOH. To stain the DNA, cells were pel-
leted, re-suspended in 100 μl EtOH and stained for 1
hour with 300 μl PI solution (0.05mg/ml PI, 20 μg/ml
RNAse A in 0.1%BSA).
Senescence analyses
SNU638 cells were seeded at 400.000 cells per 6-well-
plate and transfected with 50nM miRNA duplex
(Ambion) using Lipofectamine 2000 (Invitrogen). Four
days post-transfection, cells were washed in PBS and
fixed for 5 minutes at room temperature in 2% formal-
dehyde/0.2% glutaraldehyde. Cells were washed twice in
PBS pH6.0 before being stained with fresh senescence
associated b-Gal stain solution (1mg/ml 5-bromo-4-
chloro-3-indolyl-bD-galactoside (X-Gal), 0.12mM K3Fe
[CN]6,0 . 1 2 m MK 4Fe[CN]6,1 m MM g C l 2 in PBS pH6.0)
overnight at 37°C without CO2 supply. Cells were
washed once in PBS (pH6.0) and observed under the
microscope.
Antibodies and western blot analyses
SNU638 were seeded at 2 × 10
6 cells per 10 cm plate,
transfected twice on two successive days with 50nM
miRNA duplexes using Lipofectamine 2000 according to
manufacturer (Invitrogen). Cells were harvested by tryp-
sinization, washed once with PBS and lysed in RIPA
buffer (150mM NaCl, 0.5% Sodium Deoxycholate, 0.1%
SDS, 1% Igepal, 50mM Tris-HCl pH8, 2mM EDTA)
supplemented with 1mM DTT, 1mM Pefabloc, 1mM
NaV3, 10mM NaF and 1X complete mini protease inhi-
bitor cocktail tablets. 25 μgo fp r o t e i n / l a n ew e r e
resolved on 4-20% NuPAGE Bis-Tris gels (Invitrogen)
and transferred to a nitrocellulose membrane. Primary
antibodies used were MET (Cell Signal 4560), MYC
(Cell Signal 9402), GMNN (Santa Cruz Sc-53923), VCL
(Sigma V9131), TP53 (Santa Cruz Sc-126), CDKN1A
(Santa Cruz Sc-6246), CDK6 (Santa Cruz Sc-177),
HDAC1 (Santa Cruz Sc-7872), CCNE2 (Cell Signal
4132), TUBB (Abcam ab11304), PARP (Cell Signal
9542) and Cleaved CASP3 (Cell Signal 9661).
Microarray analyses
Small RNAs (< 200 nt) were isolated with Invitrogen
PureLink miRNA Isolation Kit from fundic and antral tis-
sue from 1) Gastrin KO mice and age and sex matched
C57BL6/J control mice, and 2) C57BL6/J mice infected
with H. Pylori and uninfected age and sex matched
C57BL6/J control mice, (n = 4 for each group). The qual-
ity of isolated small RNAs was determined using the
Small RNA Assay on an Agilent Bioanalyzer. 500ng of
small RNA was labelled with Genisphere FlashTag Kit
and hybridized to Invitrogen NCode Multi-Species
miRNA Microarray V2 in a Maui hybridization station.
Processed slides were scanned in an Agilent DNA micro-
array scanner. Resulting images was analyzed and ratio of
median normalized using GenePix Pro 6.0. Four biologi-
cal replicates were used for each comparison. Samples
were hybridized to four arrays in a dual colour dye swap
microarray experimental design. BRB ArrayTools were
used for fold change and statistical calculations. Selected
miRNA data from the array analysis were validated using
TaqMan real-time PCR miRNA assays. Data will be
deposited at ArrayExpress upon acceptance.
mRNA arrays
SNU638 were transfected with 50 nM of miR-34a or
miR-449b duplexes with siGLO siRNA used as negative
control. Total RNA was extracted 24 hours post-trans-
fection using TRIzol reagent. Affymetrix microarray ana-
lysis (HG-U133 Plus 2.0 human) was performed at the
Microarray Center, Rigshospitalet, Copenhagen Univer-
sity Hospital. Experiments were run in either triplicates
or quadruplicates. Data will be deposited at ArrayEx-
press upon acceptance.
Vectors construction and reporter assays
The 3’UTRs of HDAC1, SIRT1, MET, GMNN and
CCNE2 holding miR-449 binding sites were cloned
downstream of the luciferase reporter in pMIR-REPORT
vector system (Ambion). Quickchange site-directed
mutagenesis kit (Stratagene) was used to induce two
point mutations into the seed region. Mutagenesis pri-
mers sequences are listed in Additional file 1, table S1.
HEK293 cells were seeded in 96 well plates and trans-
fected with 20nM miRNA precursor or scrambled
siRNA control, 20-50ng of luciferase vector (pMIR-
report) and 5ng of renilla vector (pRL-TK) using lipofec-
tamine 2000 (Invitrogen). Cells were harvested 24 hours
post transfection and luciferase activity was measured
using Dual-Glo luciferase assay (Promega).
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Microarray expression data was processed using the
‘affy’ package in BioConductor [27]. Probe set intensities
were summarized and quantile normalized using the
BioConductor RMA and VSN packages. Differential
expression was determined per probeset using a t-test.
Probe sets were mapped to Ensembl transcripts (version
49) using mappings provided at BioMart. Probesets that
mapped to two different Ensembl genes were discarded.
Evaluating global down-regulation of microRNA target
genes
The 3’UTRs, 5’UTRs and coding sequences of the tran-
scripts were scanned for matching 6mer, 7mer and
8mer miRNA seed sites (complementary to position 2-7,
2-8, and 2-9 of the miRNA). Global analysis of miRNA
target down-regulation was evaluated using the longest
3’UTR sequence per gene to avoid bias introduced by
genes with many transcript isoforms. We discarded
transcripts with 3’UTR sequences shorter than 50 nt. To
globally evaluate if miRNA target genes were down-
regulated after miRNA transfection, we tested the null
hypothesis that the expression change distribution of
miRNA targets (having a 7mer target site) was equal to
the distribution of all expressed genes without predicted
target sites using the non-parametric Wilcoxon rank-
sum test. A similar approach was used to evaluate
down-regulation of genes with miRNA target sites in
coding regions and 5’UTRs of mRNAs.
Exhaustive statistical assessment of words correlated with
down-regulation
We used a previously published non-parametric rank-
based statistic to exhaustively assess the correlation of
word occurrences in 3’UTRs and the change in gene
expression after miRNA transfection [28,29]. Genes
were sorted by expression change induced by transfec-
tion of miR-34a or miR-449b, and the correlation with
down-regulation was tested for all words of length 5-7
(N = 21 504).
Statistical tests
Students t-test with Welch’s correction.
Results
miR-449b is down regulated in the antrum of both
Gastrin KO mice and H. pylori infected mice
Gastrin knockout mice are achlorhydric with a tendency
for developing antral hyperplasia and gastric adenomas
over time (figure 1) [6,12]. In order to identify micro-
RNAs deregulated during the development of gastric can-
cer, we examined miRNAs expression profiles in gastric
neoplasias from Gastrin knockout mice using miRNA
microarrays. As shown in table 1, 20 microRNAs were
significantly deregulated in the knockout mice compared
to wild type littermate controls, with three miRNAs dif-
fering more than two fold, miR-7 being up-regulated and
miR-709 and miR-449b being down-regulated in the
antrum of Gastrin knockout mice compared to wild
types. To further confirm miR-449 deregulation during
gastric cancer development, we examined its expression
in wild type mouse antrum tissues infected with
H. Pylori. Interestingly, miRNA arrays demonstrated a
specific down-regulation of miR-449b in H. Pylori
infected mice (table 2 and Additional file 1, figure S1).
miR-449 inhibits cell cycle progression and induces
senescence
Having demonstrated down-regulation of miR-449
expression in gastric cancers we wanted to examine the
effect of re-expressing miR-449 in gastric cancer cell
lines. Interestingly no noticeable expression of the miR-
449 family was detected across a panel of gastric cell
lines including SNU638, SNU5, SNU216, SNU601 and
MKN74 sustaining the notion of miR-449 having
tumour-suppressive functions (data not shown). The
miR-449 family consists of miR-449a and b in humans
and miR-449a, b and c in mice. Interestingly, they share
t h es a m es e e ds e q u e n c ea st h em i R - 3 4f a m i l ya n da r e
hence expected to regulate overlapping cohorts of target
genes (figure 2a). To assess the function of miR-449 in
gastric cell lines we re-introduced miR-449b in SNU638
and MKN74 cells. Compared to negative control micro-
RNAs, re-introduction of miR-449b strongly affected the
proliferation of SNU638 cells (figure 2b) and visual
inspection of the cells indicated induction of apoptosis
and cellular senescence (figure 2c, and Additional file 1,
figure S2). Flow cytometric analysis of propidium
iodide-stained cells transfected with miR-449b showed a
G1 accumulation 48 hours after transfection, followed
at 72 hours post transfection by an accumulation of
cells in the sub G1 fraction suggestive of cell death
(figure 2d). The induction of cellular senescence was con-
firmed by acidic beta gal staining using miR-34a as a
positive control microRNA (figure 2e). To rule out cell
line-specific effects, the functional consequences of
miR-449 re-introduction in terms of cell cycle arrest were
verified in MKN74 cells (Additional file 1, figure S3).
Thus, re-introduction of miR-449 negatively affects prolif-
eration of gastric cancer cell lines concomitant with the
induction of senescence and apoptosis in concordance
with miR-449 having tumour suppressive functions.
The joint seed sequence of miR-449b and miR-34a induce
highly correlated expression changes
To characterize the transcripts controlled by miR-449 and
to see if miR-449 regulates different transcripts than
miR-34a, SNU638 cells expression profiles were examined
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differentially expressed transcripts identified. We found
that mRNAs with predicted miRNA target sites (7 mer
seed site) in the 3’UTR were significantly down-regulated
compared to mRNAs without predicted target sites after
transfection of miR-449b (p < 1.2e-70, two-tailed Wil-
coxon rank-sum test), (Additional file 1, figure S4a).
mRNAs having predicted miRNA seed target sites in
coding regions were also found to be significantly down-
regulated (p < 9.9e-25), while mRNAs with sites in 5’UTRs
were only marginally down-regulated (p < 5.3e-2). The
expression changes induced by transfection of mature
miR-449b and miR-34a were highly correlated despite
divergence of the mature sequences outside the seed
region (Pearson’s correlation coefficient R = 0.94, p = 0),
(Additional file 1, figure S4b). We exhaustively evaluated
all oligonucleotides (words) of length 5-7 for correlation
with down-regulation after miR-449b and miR-34a trans-
fection (see methods). Consistent with many previous stu-
dies, this analysis revealed the shared miR-34a/449b seed
site as the 3’UTR word most correlated with down-regula-
tion in the two experiments (Additional file 1, figure S4c).
miR-449 regulates numerous cell cycle controllers
The expression profiles wereu s e dt oi d e n t i f yd i f f e r e n -
tially expressed transcripts in cells transfected with
miR-449b or controls (Additional file 1, table S2).
Figure 1 Old Gastrin knockout mice develop gastric adenomas. Antrum sections isolated from 12-16 weeks old mice (left panel), 12 to 18
months old mice (middle panel) and older than 18 months mice (right panel), from wild type (upper panel) and Gastrin knockout mice (lower
panel). Sections show adenoma development in antrum tissues in the Gastrin knockouts compared to the wild types.
Table 1 miRNAs deregulated in Gastrin knockout mice
miRNA
Name
Log2-
fold
p-
value
miRNA Name Log2-
fold
p-
value
mmu-miR-709 -1.73 7.0E-06 mmu-miR-422b 0.44 4.6E-02
mmu-miR-
449b
-1.37 1.6E-03 mmu-miR-199a* 0.50 7.7E-03
mmu-miR-805 -1.01 7.5E-03 mmu-miR-25 0.51 1.6E-02
mmu-miR-706 -0.98 3.1E-03 mmu-miR-27b 0.56 5.1E-03
mmu-miR-
467a
-0.88 2.8E-02 mmu-miR-182 0.56 1.8E-02
mmu-miR-696 -0.83 7.1E-03 mmu-miR-30a-
3p
0.59 2.2E-02
mmu-miR-667 -0.66 2.3E-02 mmu-miR-10a 0.70 7.1E-03
mmu-miR-690 -0.28 1.7E-02 mmu-miR-152 0.70 2.3E-02
mmu-miR-18 0.29 3.7E-02 mmu-miR-1 0.77 7.1E-03
mmu-miR-143 0.34 2.3E-02 mmu-miR-7 1.06 4.9E-03
List of significantly deregulated miRNAs in gastric neoplasias from Gastrin
Knockout mice compared to wild types.
Table 2 miRNAs deregulated in H.Pylori infected tissues
miRNA name Fold change p-value
mmu-miR-122a -3.247 0.000788
mmu-miR-449b -0.879 0.045214
List of significantly deregulated miRNAs in wild type mice antrum infected
with H. Pylori compared to non-infected antrum.
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tially regulated transcripts demonstrates that miR-449
mainly controls transcripts coding for proteins
involved in cell damage responses, cell cycle control,
inflammation and cancer pathways (figure 3a).
Focusing on a set of putative target genes with well-
established roles in tumourigenesis, we confirmed
down-regulation by miR-449 of met proto oncogene
(MET), cyclin dependent kinase 6 (CDK6), geminin
(GMNN), myelocytomatosis viral oncogenes homolog
(MYC), sirtuin 1 (SIRT1) and histone deacetylase 1
(HDAC1) at the transcript level (figure 3b). Western
blot analyses confirmed the ability of miR-449 to
down-regulate MET, GMNN, MYC, SIRT1, cyclin E2
(CCNE2) and HDAC1 at the protein level to an extent
similar to that achieved by re-introduction of miR-34a
(figure 3c). For a subset of target genes including
MET, GMNN, CCNE2, SIRT1 and HDAC1,w ec o n -
firmed direct interaction of miR-449 with the target
gene 3’ UTR using luciferase assay (figure 3d).
Hence, miR-449 directly targets cell cycle regulator
genes consistent with a tumour suppressor function and
with the cell cycle arrest observed upon miR-449 re-
introduction into cancer cell lines.
Figure 2 miR-449 is part of the miR-34 family and inhibits cell proliferation. A - miR-449 is part of the miR-34 family and is evolutionarily
conserved. B - miR-449 re-introduction into human gastric cell lines (SNU638) inhibits cell proliferation (red line) compared to a scrambled
control (blue line) and miR-146 control (black line). Error bars represent S.D. C - Visual inspection of cell proliferation inhibition and senescence-
like phenotype upon miR-449 re-introduction into SNU638 cells (lower panel) compared to scrambled transfection control (upper panel). D -
FACS cell cycle analysis showing sub-G1 accumulation of SNU638 cells 72 hours following miR-449 re-introduction (right histogram) compared to
a scrambled transfection control (left histogram) The table shows cell accumulation in G1 fraction upon miR-449 re-introduction compared to
scrambled RNA control at 48 hours post transfection, followed by a shift to the sub-G1 fraction at 72 hours post transfection indicative of cell
death. E - Senescent phenotype of SNU638 cells upon miR-449 and miR-34a positive control re-introduction shown by acidic b-gal assay
compared to RNA scrambled control.
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regulated by p53
As miR-34a was previously found to function down-
stream of p53 [30-33], we analyzed if also miR-449a/b
were linked to p53. This was furthermore spurred by
the presence of a putative p53 binding site 10 kb
upstream from human miR-449 (data not shown). We
therefore induced p53 by DNA damage using UV or 5-
fluorouracil (5FU) in four different systems, HCT116
and MEF wild type and p53 knockout cells (Additional
file 1, figure S5a). However, no significant change in
miR-449 expression was detected after p53 pathway
activation (Additional file 1, figure S5b). In conclusion,
we found no evidence that miR-449 is a transcriptional
target of p53. On the other hand, we found that miR-
449a/b is able to induce activation of p53, activation of
p53 response genes such as p21 and the induction of
apoptosis as evidenced by cleavage of caspase 3 (CASP3)
and poly (ADP-ribose) polymerase 1 (PARP) (figure 4).
Towards understanding the mechanism by which miR-
449 does this we examined the effect of miR-449 on
SIRT1 and HDAC1. SIRT1 and HDAC1 are deacetylases
which inhibit, among others, the activation of p53
and miR-34 has been shown to repress SIRT1 [34].
Figure 3 miR-449 targets cell cycle controller genes. A - Ingenuity Pathway Analysis (IPA) of deregulated genes upon miR-449 re-
introduction into SNU638 cells showing enrichment for the gene categories cancer, cell death and cell cycle pathways among others. B - qPCR
validation of Affymetrix arrays showing down-regulation of MET, CDK6, GMNN, MYC and HDAC1 upon miR-449 re-introduction compared to
scrambled RNA controls. C - Western blot validation of down-regulated genes upon miR-449 re-introduction into SNU638 cells compared to
scrambled RNA controls. Vinculin (VCL) and tubulin beta (TUBB) were used as loading controls D - verification of direct and functional target
binding using luciferase constructs holding wild type 3’UTRs and mutated 3’UTRs (two mutations in miR-449 binding site), * indicates statistical
significance in luciferase expression between wild type 3’UTRs transfected with miR449a/b compared to RNA scrambled control, # indicates
statistical difference in luciferase expression between wild type 3’UTRs compared to mutant 3’UTRs transfected with miR-449a and miR-449b. “ns”
not significant p value > 0.05, “*” or “#” significant 0.01 < p value < 0.05, “**” or “##” very significant 0.01 < p value < 0.001, “***” or “###”
extremely significant p value < 0.001.
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and HDAC1 using 3’UTR luciferase assays (figure 3d).
Hence, we speculate that miR-449 induces apoptosis
by inhibiting the histone deacetylase HDAC1 and SIRT1
leading to the p53 pathway activation thus the induction
of apoptosis markers cleaved CASP3 and PARP.
miR-449 is down-regulated in human gastric cancers
To evaluate the importance of miR-449 in human
malignancies we next examined the expression of miR-
449 in 10 gastric cancer biopsies. Importantly, we found
both miR-449a and b to be significantly down-regulated
or absent in 8 out of 10 primary gastric cancers.
Furthermore, the expression of miR-449a and b seem to
be co-regulated (figure 5a). We did not find any correla-
tion between the reduction in miR-449 expression and
clinical characteristics of the cancer (figure 5b). Analyses
of the genomic DNA from the tumours found no evi-
dence for loss or hyper-methylation of the miR-449 loci
using methylation-specific melting curve analysis (MS-
MCA) indicating transcriptional down-regulation of
expression (data not shown). Hence, in agreement with
data from two mouse models of gastric inflammation
and hyperplasia, the expression of miR-449 is down-
regulated in human gastric cancers.
Discussion
Gastric cancer is a highly lethal malignancy with more
than 21,500 new cases each year in the United States
alone [35]. The disease is often detected late and the
5-year survival rate is consequently below 20% [36]. It
is therefore important to understand the etiology and
progression stages of the disease. The importance of
the bacterial, environmental and host genetic risk fac-
tors in gastric carcinogenesis have been studied, how-
ever less is known about the molecular progression of
the disease [37,38]. Among others, p53 pathway inacti-
vation is reported in 30-60% of gastric cancers [39,40]
and recent studies suggest H. pylori direct modulation
of the p53 gene or its downstream targets [41].
Another common alteration in gastric cancer is the
perturbation of the cell cycle control via the over
expression of Cyclin E1, which is associated with
tumour aggressiveness and lymph node metastasis
[42,43]. In contrast to our current understanding of
the role of tumour suppressors and cell cycle factors,
the knowledge about the post transcriptional changes
affecting gene expression in gastric cancer is still
incomplete.
Using the Gastrin knockout mouse model for gastric
cancer [6,12], we identify 20 deregulated microRNAs of
which 3 were more than 2-fold deregulated relative to
their levels in normal gastric mucosa. As infection with
H. pylori has been causally linked to gastric cancer
[44,45], we next examined changes in microRNA
expression levels following infection of wild type mice
with H. Pylori. Interestingly, miR-449b was the only
miRNA significantly deregulated in both mouse models.
To establish a causal relationship between miR-449
deregulation and cancer-relevant parameters, such as
cell cycle regulation, apoptosis and senescence, we over-
expressed miR-449 in gastric cancer cell lines and
observed a significant down-regulation of proliferation
coupled with up-regulation of the acidic beta-gal senes-
cence marker and induction of apoptosis. Importantly,
analyses of primary gastric tumours from patients clearly
documented a tumour-specific down-regulation of miR-
449 also in humans. Previously, a number of studies
have demonstrated deregulation of miRNA in gastric
cancer [46-50] and the importance of the entire micro-
RNA system has been documented in both gastric and
colon cancer by the presence of cancer-specific muta-
tions in the key RISC components AGO2 and TNRC6A
[51]. Furthermore, microRNAs are likely of important
prognostic value in gastric cancer [52-54]. The
present study represents the first report demonstrating
Figure 4 miR-449 activates the p53 pathway. Western blot analysis showing an increase of the p53 protein upon miR-449 and positive
control miR-34a re-introduction into SNU638 cells compared to RNA scrambled control as well as an activation of the p53 downstream target
p21 and apoptosis markers cleaved CASP3 and PARP. Vinculin (VCL) and tubulin beta (TUBB) were used as loading controls.
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Page 8 of 12cancer-related down-regulation of miR-449 in both
mouse models for gastric cancer and in primary human
gastric tumours. Beside gastric cancer, the expression of
miR-449 has also been found to be reduced in several
cell lines [55] and in prostate cancer, where it was
found to target HDAC1 and induce growth arrest
following over-expression in prostate cancer cells [56].
In contrast, the expression of miR-449 has been
reported to be increased in endometrioid adenocarci-
noma [57] and melanoma in young adult patients [58].
The expression of miR-449 was also increased in skeletal
muscle damage and regeneration [59].
Figure 5 miR-449 is down regulated in human gastric cancers. qPCR analysis (upper panel) showing down-regulation of miR-449 expression
in 8 gastric cancer tissues compared to miR-449 expression in sample-matched controls (dotted line). U44 was used as endogenous control.
Table showing clinical information of patients (lower panel). “ns” not significant p value > 0.05, “*” significant 0.01 < p value < 0.05, “**” very
significant 0.01 < p value < 0.001, “***” extremely significant p value < 0.001.
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and cancer progression or initiation we experimentally
identified a number of direct mRNA targets using tran-
scriptional profiling and extensive bioinformatics analy-
sis. A series of the putative miR-449 targets were
subsequently validated at endogenous level using wes-
tern blotting and quantitative PCR and their direct regu-
lation by miR-449 was established using heterologous
reporter constructs and binding site-specific mutation
studies. Prominent validated targets include CDK6,
MYC, CCNE2, MET and GMNN and we furthermore
validated the regulation of HDAC1 and SIRT1 also in
gastric cancer cells. Hence, the cancer-specific loss or
down-regulation of miR-449 in gastric cancer can likely
be explained by the connection to key cell cycle regula-
tors. During the search for miR-449 targets we also
identified several growth factors (AREG,a n dKITLG)
and growth factor receptors, such as MET,a st a r g e t s .
This suggests that deregulation of miR-449 not only
leads to deregulated control of cell cycle proteins but
also of growth factors and their receptors. Thus, another
important property of miR-449 could be as a regulator
of signals important for growth and migration/invasion.
Interestingly, miR-449 was recently shown to operate
under the control of E2F1 [55,60]. This is highly inter-
esting as it places miR-449 at a key node in a feed-back
loop in which E2F1 activates the transcription of miR-
449 that in turn targets CDC25A and CDK6. Reduced
levels of CDC25A and CDK6 decreases the phosphoryla-
tion of pRB and subsequently inhibits the release of
E2F1 [55,60,61]. Hence, aside from the pro-oncogenic
effects of up-regulation of MYC, MET, CCNE2 and
other direct targets, loss of miR-449 may result in
increased E2F1 activity.
Many of the direct mRNA targets for miR-449 identi-
fied in this study are also targets of miR-34a and miR-
449 and miR-34a belong to the same family of miRNAs
as they share the same seed sequence. In accordance,
miR-34a has been demonstrated to act as an important
tumour-suppressor miRNA and reduced expression of
miR-34a has been reported for neuroblastoma [62] and
many other cancers [63]. In addition, the miR-34a gene is
activated by p53 following DNA damage [30-33] and by
ELK1 following over-expression of activated B-RAF [64].
In the present study, transcriptional profiling demon-
s t r a t e dt h a to v e r - e x p r e ssion of miR-449 or miR-34a
results in identical transcriptome changes. While this is
underlining the dominant importance of the seed
sequence in this type of over-expression study it also
points to a limitation in the experimental approach.
While miR-449 was clearly down-regulated or lost in
the analyzed mouse tumour samples no clear tendency
for loss or down-regulation of miR-34a was observed
(data not shown). This indicates that these microRNAs
may have more deviant functions in vivo than suggested
by the over-expression studies.
Finally, we examined the relationship between the p53
tumour suppressor and miR-449. As miR-34a has been
firmly placed downstream from p53 [30-33] it was relevant
to test if the same was the case for miR-449. In agreement
with other studies [55,60], we did not observe a p53-
dependent regulation of miR-449 in gastric cancer cells as
well as in primary human and mouse fibroblasts. However,
in agreement with previous findings for miR-34a, we find
that miR-449 regulates the expression of p53 [31,32] as
over-expression of miR-449 resulted in a potent up-regula-
tion of p53 subsequently resulting in activation of p21 and
induction of apoptosis markers, such as cleaved CASP3
and PARP as previously reported [60].
In summary, we have found that miR-449 may act as a
tumour suppressor and is lost in gastric cancer. Its re-
introduction into cancer cell lines leads to inhibition of
cell proliferation by targeting different cell cycle regulators.
We also found that re-introduction of miR-449 induces
senescence and apoptosis. Hence, this study further under-
lines the importance of miRNAs in cancer and points to
an important function for miR-449 in gastric cancer.
Additional material
Additional file 1: Figure S1 - miR-449 is down-regulated in Gastrin
knock out mice compared to wild type. qPCR analysis of miR-449
expression in Gastrin knock out gastric tissues compared to relative
expression in wild type gastric tissues, miR-449 is significantly down-
regulated (p = 0.04) in Gastrin knock out tissues compared to wild types.
Figure S2 - miR-449 inhibits cell proliferation in human gastric
cancer cell line MKN74. Visual inspection of human gastric cancer cell
line (MKN74) upon miR-449 re-introduction (lower panel) showing a
decrease in cell proliferation as well as a senescent like phenotype
compared to scrambled RNA control (upper panel) Figure S3 - miR-449
induces cell death in human gastric cancer cell line MKN74. FACS
cell cycle analysis of MKN74 cell line upon miR-449 re-introduction (right
histogram) showing an increase in the sub-G1 fraction indicative of cell
death compared to scrambled RNA control (left histogram), table
showing percentage of cell accumulation in G1 fraction 48 hours post
miR-449 re-introduction followed by cell shift to the sub-G1 fraction 72
hours post transfection compared to RNA scrambled control. Figure S4 -
miR-449b and miR-34a induce highly correlated expression
changes. A - Chart showing significant down-regulation (p < 1.2e-70) of
mRNAs with predicted miR-449 seed match in their 3’UTR (red line)
compared to mRNAs lacking the seed match (black line). B - Chart
showing high correlation of expression changes upon re-introduction of
miR-449b or miR-34a into SNU638 cells with a Pearson’s correlation
coefficient of r = 0.94, p = 0. C - Word analysis showing shared miR-
449b/34a seed site correlating with gene down-regulation. Figure S5 -
miR-449 expression is p53 independent. A -Western blot showing p53
induction in HCT116 wild types and p53 knockouts using 5FU. B - qPCR
analyses of miR-449a and miR-449b post p53 induction. No significant
change is observed. Table S1 - primer sequences. Table S2 - list of
genes deregulated upon miR-449 re-introduction. Affymetrix top
down-regulated genes upon miR-449 re-introduction into SNU638 cells.
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